Study of Amish suggests mutation linked to longer life span

November 15, 2017

A particular mutation identified among Old Order Amish in Indiana is associated with a longer life span, improved metabolism and a lower occurrence of diabetes, according to a new study. The findings demonstrate the utility of studying mutations in populations with geographic and genetic isolation, and shed light on a novel therapeutic target for aging. Aging remains one of the most challenging biologic processes for scientists to unravel, due in part to the many interrelated molecular and cellular changes it brings. One indicator of aging is the shortening of telomeres, caps at the end of strands of DNA that protect a person's chromosomes. Progressive shortening of telomeres leads to senescence, or biological aging. Senescent cells and tissues exhibit a distinctive pattern of protein expression, including increased production of plasminogen activator inhibitor-1 (PAI-1). To further examine the role of PAI-1 in human longevity, Sadiya Khan and colleagues studied 177 members of the Berne Amish community. Forty-three of these men and women carried a nonfunctional copy of the gene SERPINE1, which encodes PAI-1. Carriers of this SERPINE1 mutation lived an average of 10 years longer than other individuals in the community. What's more, they had a 10% longer average white blood cell telomere length, after adjusting for age, sex, and familial relatedness compared with noncarriers. The authors say future studies will be needed to investigate the contribution of PAI-1 to individual telomere shortening over time, the development of incident diabetes, and other age-related diseases, and perhaps ultimately differences in health and lifespan in humans.

American Association for the Advancement of Science

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to